

Kneat and HCL Technologies Partner to Deliver Digital Validation Solutions to Life Sciences

February 21, 2019 1:00 PM EST

HALIFAX, February 21, 2019/CNW/ – kneat.com, inc. (TSX-V: KSI) ("Kneat") is pleased to announce that it has signed a partnership agreement with HCL Technologies ("HCL"), a leading global technology company, to provide innovative end-to-end digital validation solutions to customers in the life sciences industry. HCL has an impressive network and track record within this industry; having decades of experience servicing many of the top bio-pharmaceutical, medical device, contract research, and contract development and manufacturing organizations in the world.

This partnership represents a key element in Kneat's strategy to deliver greater value to its current customers and to grow and scale to new customers. Kneat and HCL will work together on projects to provide and implement next generation digital solutions for facilities, equipment and computer systems validation processes using Kneat's paperless software platform and HCL's experience delivering innovative digital solutions to the life sciences industry.

"This partnership with HCL comes at a pivotal time as the life sciences industry is searching for digital solutions to create efficient and compliant validation processes." said Eddie Ryan, Chief Executive Officer of Kneat. "We look forward to working with HCL to enhance the value that we deliver to both our customer bases."

"Our partnership with Kneat will further enable us to help our clients disrupt the marketplace with more agile, leaner and standardized validation lifecycle management solutions and services" said Shrikanth Shetty, Executive Vice President – Head Lifesciences & Healthcare Vertical at HCL Technologies. "We are excited to work with Kneat to further catalyse the digital journey of our clients and enhance overall quality confidence and speed."

About HCL

HCL Technologies (HCL) is a leading global technology company that helps global enterprises reimagine and transform their businesses through Digital technology transformation. The Life Sciences division of HCL Technologies helps clients reimagine their businesses for the digital age through an integrated portfolio of products, solutions and services. Our solutions are built around digital, IoT, cloud, automation, cybersecurity, analytics, infrastructure management, and engineering services, among others. Over decades HCL's validation practice has been partnering with life sciences clients for many leading transformational and run-the-business initiatives. Our 10,000+ Life Sciences Ideapreneurs across 43 countries deliver innovation for over 80% of world's leading life sciences companies in all strategic and functional areas—with a strong focus on R&D, sales and marketing, patient services and supply chain & manufacturing and compliance. For more information, please visit www.hcltech.com or contact contact.lsh@hcl.com

About Kneat

Kneat, develops and markets the next generation Kneat Gx software platform. Multiple business processes can be configured on the platform from equipment to computer system validation, through to production record execution and quality document management. Kneat Gx allows users to author, review, approve, execute testing online, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform. Macro and micro report dashboards enable powerful oversight into all systems, projects and processes world wide. Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard. For more information visit www.kneat.com.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes "forward-looking information" within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the relationship between Kneat and the customer, the Company's business development activities, the use of Kneat within the customer's manufacturing process, the ability to scale the use of Kneat within the customer and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investors' own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information: Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com